Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.76 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.76 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.76 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.76 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.76 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Funapide SCHEMBL1612874 | 0.87 | SCN9A (1.00) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| Funapide SCHEMBL281394 | 0.87 | SCN9A (1.00) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| Funapide SCHEMBL29379143 | 0.87 | SCN9A (1.00) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| Funapide SCHEMBL1612849 | 0.87 | SCN9A (1.00) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3604833 | 0.83 | SCN9A (0.59) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3589126 | 0.82 | SCN9A (1.00) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL12712202 | 0.81 | SCN9A (0.89) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2309587 | 0.81 | SCN9A (0.89) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL2305585 | 0.81 | SCN9A (0.89) | SCN9ASCN7ASCN5ASCN2ASCN8A | |
| SCHEMBL3600318 | 0.81 | SCN9A (0.56) | SCN9ASCN7ASCN5ASCN2ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294842-A9 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2011-12-01 | — | — | US | claimed |
| US-20100160362-A1 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | claimed |
| US-20110294842-A9 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2011-12-01 | — | — | US | disclosed |
| US-20110294842-A9 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2011-12-01 | — | — | US | disclosed |
| US-20110294842-A9 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2011-12-01 | — | — | US | disclosed |
| US-20100160362-A1 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | disclosed |
| US-20100160362-A1 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | disclosed |
| US-20100160362-A1 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | XENON PHARMACEUTICALS INC. (CA) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160362-A1 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | SCN3A, SCN1B, SCN2B | SCN9A 38/4885SCN7A 64/4885SCN5A 36/4885 |
| US-20110294842-A9 | SPIRO (FURO [3, 2-C] PYRIDINE-3-3' -INDOL) -2' (1'H)-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SODIUM-CHANNEL MEDIATED DISEASES, SUCH AS PAIN | SCN3A, SCN1B, SCN2B | SCN9A 38/4885SCN7A 64/4885SCN5A 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.